From 1st September 2026 Pharmac have amended the Special Authority criteria for empagliflozin (Jardiance), empagliflozin with metformin (Jardiamet), dulaglutide (Trulicity) and liraglutide (Victoza). These medicines will now be available to all people living with T2DM who are continue to have blood glucose levels (HbA1c) above 53 mmol/mol despite using other funded diabetes medicines. Dual funding of empagliflozin (Jardiance) and GLP1Ra is only possible for people with type 2 diabetes and heart failure, so people with T2D and heart failure should ideally be on funded empagliflozin under the heart failure special authority criteria and funded GLP1Ra under the diabetes special authority if the HbA1c remains above target. Changes in response to these new Special Authority criteria have been made throughout the guideline.